pharmaphorum May 15, 2024
AbbVie has joined the short list of big pharma companies that have taken a gamble on the emerging field of psychedelic medicines, paying $65 million on an option deal with start-up Gilgamesh Pharma.
The two companies will work together on the development of a “next-generation” of psychedelic medicines for psychiatric disorders, although – for now – the drugs themselves and the target indications are being kept under wraps.
AbbVie has also promised up to $1.95 billion in option fees and milestone payments for a series of ‘neuroplastogens’, therapies that tap into the mechanisms of the current wave of psychedelics, but will be designed to reduce their psychoactive effects – such as hallucinations – that mean they have to be delivered...
Today's Sponsors
Today's Sponsor